Ironwood Q1 revenue jumps 159%, beats analyst expectations

Ironwood Pharmaceuticals

07/05/2026 12:19

Overview

U.S. GI drugmaker's Q1 revenue rose sharply, beating analyst expectations

Adjusted net income for Q1 beat analyst expectations

Company maintained 2026 financial guidance and advanced Phase 3 apraglutide trial plans

Outlook

Ironwood maintains 2026 guidance for LINZESS U.S. net sales at $1.125-$1.175 bln

Company expects 2026 total revenue of $450-$475 mln

Ironwood projects 2026 adjusted EBITDA above $300 mln

Result Drivers

LINZESS NET PRICE - Co said significantly improved net price, due to elimination of inflationary rebates and favorable time-phasing of gross-to-net rebate reserves, was a primary driver of Q1 LINZESS U.S. net sales growth

PRESCRIPTION DEMAND - 5% year-over-year growth in LINZESS prescription demand contributed to higher sales

LOWER OPERATING EXPENSES - Decline in total costs and expenses, including lower SG&A and restructuring costs, supported improved profitability

Company press release: ID:nBw99z8W3a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$106.51 mln
$92.09 mln (4 Analysts)
Q1 EPS
$0.24
Q1 Adjusted Net Income
Beat
$40.95 mln
$38.20 mln (3 Analysts)
Q1 Net Income
$40.77 mln
Q1 Adjusted EBITDA
Beat
$76.67 mln
$49.35 mln (2 Analysts)
Q1 Basic EPS
$0.25


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)